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All knockout mouse models of urea cycle disorders die in the neonatal period or 
shortly thereafter. Since N-acetylglutamate synthase (NAGS) deficiency in humans 
can be effectively treated with N-carbamyl-L-glutamate (NCG), we sought to develop 
a mouse model of this disorder that could be rescued by biochemical intervention, 
reared to adulthood, reproduce, and become a novel animal model for 
hyperammonemia. NCG and L-citrulline (Cit) were used to rescue the NAGS 
knockout homozygous (Nags-/-) pups and the rescued animals were characterized. 
This regimen has allowed for normal development, apparent health, and reproduction. 
Interruption of this rescue intervention resulted in the development of severe 
hyperammonemia and death within 48 hours. We have developed a home cage 
behavioral system that allows to monitor and analyze the chronology of animal 
  
behaviors during healthy and hyperammonemic states. Data collected from this study 
reveals that mice decrease their normal activity around 12 hours and become severely 
lethargic by 20 hours following NCG withdrawal. Understanding the chronology of 
hyperammonemia will aid in future studies to discover neuro-protective drugs for 
treating hyperammonemia. This mouse model will also allow studies of the 
pharmacokinetics and pharmacodynamics of NCG, much of which is still unknown. 
Understanding how NCG is transported into cells and then cleared is clinically 
relevant and can potentially lead to more efficient administration of this drug. We 
conclude that a novel NAGS deprived mouse model has been developed which can be 
rescued by NCG and Cit and reared to reproduction and beyond. This biochemically 
salvageable mouse model recapitulates the clinical phenotype of proximal urea cycle 
disorders and can be used as a reliable model of induced hyperammonemia by 
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The urea cycle, discovered by Hans Krebs in 1932, is a biochemical process that 
converts toxic ammonia to urea [1,2]. Ammonia is a source of nitrogen waste from 
multiple biochemical processes: hydrolysis of urea and nitrogenous compounds by urease 
positive gut bacteria, catabolism of dietary proteins, and catabolism of cellular proteins, 
including skeletal muscle during exercise [3,4]. A healthy adult will produce an average of 
0.3-1.2 moles of nitrogen a day; more than 90% of which is excreted in the form of urea to 
maintain plasma ammonia concentration of less than 35 µM [3]. Ammonia enters the liver 
via the portal vein (Figure 1) where concentrations of ammonia can be up to 350 µM 
(about 10-fold higher than in the systemic blood). The liver removes almost all the 
ammonia in one pass, utilizing two main pathways expressed in two different forms of 
hepatocytes; the urea cycle in the periportal hepatocytes and glutamine synthase in 
perivenous hepatocytes. Approximately two-thirds of the ammonia detoxification occurs 
via the urea cycle [3].  
The urea cycle requires at least eight proteins for proper function. Ureagenesis is 
initiated in the mitochondria by the activation of carbamyl phosphate synthetase 1 (CPS1) 
by N-acetylglutamate (NAG). NAG is produced by N-acetylgutamate synthase (NAGS) 
from L-glutamate and acetyl-CoA [5,6]. CPS1 condenses ammonia (NH3), bicarbonate 





Figure 1. The liver detoxifies ammonia.  
Ammonia produced mainly by the intestine enters the liver via the portal vein where it is 




Ornithine transcarbamylase (OTC) then condenses CP and ornithine to form citrulline [5]. 
Citrulline is then transported out of the mitochondria into the cytoplasm where it 
condenses with aspartate via the enzyme argininosuccinate synthase (ASS) to form 
argininosuccinate. The enzyme argininosuccinate lyase (ASL) then cleaves 
argininosuccinate into arginine and fumarate. Lastly, arginase I (ARG1) hydrolyzes 
arginine to form ornithine and urea.  Urea produced in the liver is excreted from the body 
through the kidneys and ornithine is transported back into the mitochondria to re-enter the 
urea cycle. In addition to these six enzymes, there are two mitochondrial transporters in 
the urea cycle. The ornithine transporter (ORNT1) transports citrulline out of the 
mitochondria and ornithine in [7,8]. Citrin transports aspartate out and glutamate into 





Figure 2. The Urea Cycle in Liver Cell.  
The proximal urea cycle enzymes, NAGS, CPS1, and OTC are expressed in the 
mitochondria, and the distal urea cycle enzymes ASS, ASL, and ARGI are expressed in 
the cytosol. (Source: Caldovic et al [9]) 
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Urea Cycle in the Liver Protects the Brain from Hyperammonemia 
 
The urea cycle is essential for protecting the brain from the toxic effects of 
ammonia. In general, the ammonia level in the plasma remains low (less than 35 µmol/L). 
However, there are numerous conditions that can cause an accumulation of excess 
ammonia. Hyperammonemia is caused by urea cycle defects, defects in fatty acid 
oxidation, cirrhosis, acute liver failure, certain surgeries, Reye syndrome, and 
chemotherapy [1,4,10]. The accumulation of excess ammonia in the plasma, 
hyperammonemia, has negative consequences on the brain with resulting symptoms of 
vomiting, lethargy, slurred speech, weakness, ataxia, seizures, and if untreated, coma and 
death [4,10,11].  
Ammonia rapidly enters the brain and rapidly combines with glutamate to generate 
glutamine via glutamine synthase, which is expressed in astrocytes [3,10-13]. Under 
physiological conditions, this enzyme functions at maximal capacity, and thus is not 
induced during hyperammonemia [3,4,10,12,13]. The autopsies of patients that have died 
from hyperammonemia show gross cerebral edema and astrocytic swelling [4,10,14]. 
Evidence suggests that the accumulation of glutamine is related to cerebral edema, first by 
osmotic action [14,15], then by increasing inner mitochondrial membrane permeability 
and lastly through free radical damage [11,15]. Studies using the glutamine synthase 
inhibitor methionine sulfoximine show reduced ammonia-induced brain edema both in 
vivo and in vitro [11,16,17]. 
Cerebral edema may also be caused by a change of Aquaporin 4 channels, which 
are involved in water homeostasis [13,16,17]. Additionally, ammonia can be transported 
through the astrocytic potassium channels Kir 4.1 and Kir 5.1; hyperammonemia blocks 
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potassium transport which results in extracellular potassium accumulation and neuronal 
depolarization [13,18,19].  
Alterations in the neurotransmitter receptor N-methyl-D-aspartate (NMDA) have 
also been described in hyperammonemia. The NMDA receptor is both ligand gated and 
voltage dependent. Activation of the receptor by glutamate and glycine opens the ion 
channels, which cause influx of Na+, Ca2+, and efflux of K+. Ammonia toxicity can result 
in excess extracellular glutamate, due to pH and Ca2+-dependent release of glutamate and 
then inhibition of glutamine uptake by astrocytes. The increase of extracellular glutamate 
causes overstimulation of the NMDA receptor which results in excessive influx of Na+, 
Ca2+, and Cl-, ultimately causing cell swelling and neurodegeneration [18,19].  
Administration of the drug memantine, a noncompetitive NMDA receptor antagonist, to 
rats experiencing encephalopathy, resulted in improved electroencephalography (EEG) 
activity, less increase in glutamine, and decreased intracranial pressure and brain water 
compared to non-treated encephalopathic rats [19,20]. Administration of another NMDA 
receptor antagonist, MK-801, protected against acute liver failure induced death, 
increasing survival time two-fold [20].  
These studies show that separately, astrocytes and NMDA receptors on neurons 
play a role in the neurological symptoms of hyperammonemia, and the administration of 
drugs that target these cells can attenuate hyperammonemia. It is unknown how these two 
mechanisms connect, and if a combination of drugs can lead to the maximal blocking of 
cerebral edema or reverse the neurological symptoms of hyperammonemia. Additionally, 
studies on the mechanisms underlying hyperammonemia have not yet explained the 
clinical symptoms presented in patients. 
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Urea Cycle Enzymes in Arginine Production 
 
Though the urea cycle produces arginine, there is no net arginine production from 
the liver because the high levels of ARGI hydrolyze arginine to ornithine and urea. 
Instead, the small intestine and kidneys are tasked with producing endogenous arginine. 
First, intestinal epithelial cells convert glutamine to citrulline. Glutamine is the most 
abundant amino acid in the cells and the plasma, where it serves as both an ammonia 
scavenger and a nitrogen donor [21]. The intestine has access to glutamine from two 
sources: the intestinal lumen and the arterial supply. Within the mitochondria of the 
intestinal epithelial cells, glutamine is first converted to glutamate via glutaminase. Then, 
pyrroline-5-carboxylate synthase converts glutamate to pyrroline-5-carboxylate or 
glutamate semialdehyde [22-26]. Next, proline-5-carboxylate or glutamate semialdehyde 
is transaminated via ornithine aminotransferase to form ornithine. NAGS, CPS1, and OTC 
are also present in the mitochondria of intestinal epithelial cells where they perform the 
same role as in the hepatocytes [22,24,27,28]. CP produced from CPS1 activity condenses 
with ornithine via ornithine transcarbamylase to yield citrulline. The citrulline is then 
released into the blood where it bypasses the liver and enters the renal artery [27-29]. ASS 
and ASL are expressed in the proximal convoluted tubules where citrulline is converted to 
arginine [29] (Figure 3). Arginine is necessary for many physiological processes, 
including protein building, creatine production, NO production, and wound repair (Figure 









   
 
 
Figure 3. Arginine synthesis via the intestinal-renal axis.  
Citrulline is produced in small intestinal epithelial cells, bypasses the liver, and is 






Figure 4. Metabolic Fates of Arginine.  
Arginine is a precursor for multiple biochemical pathways, including the production of 
nitric oxide  (NO), proline, glutamate, polyamines, and creatine. iNOS=inducible nitric 
oxide synthase, ARG1= arginase I, OAT= ornithine aminotransferase, AGAT=arginine 
glycine amidinotransferase, ODC= ornithine decarboxylase.   
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N-Acetylglutamate Synthase Deficiency 
 
For all eight urea cycle associated proteins, there are documented cases of patients 
showing a genetic deficiency. NAGS deficiency is the rarest of the urea cycle disorders, 
with only 34 reported cases from 28 families [30-32]. The first case of NAGS deficiency 
was described in 1981 [30]. A deficiency in any of the urea cycle enzymes manifests as 
hyperammonemia, which results in vomiting, seizures, mental retardation, coma, and 
death if left untreated [14,31,32]. The biochemical symptoms of NAGS deficiency are 
identical to those of CPS1 deficiency and include elevated plasma ammonia and 
glutamine and reduced levels of urea cycle intermediates arginine, citrulline, and ornithine 
[32-35].  Due to the identification of the NAGS gene by our laboratory in 2002 [33-35], 
NAGS deficiency can now be definitively confirmed genetically. This autosomal 
recessive disease has varying degrees of severity. Patients presenting in the neonatal 
period tend to have nonsense or frameshift mutations that result in complete absence of 
the NAGS protein [36-41], while missense mutations may allow for some residual NAGS 
enzyme activity and present after the neonatal period [31,36,38,40,42]. There are also 
documented “late-onset” cases that have presented during adulthood [31,42,43]. 
N-Carbamylglutamate as treatment for NAGS deficiency 
 
When a patient is first suspected as having a urea cycle disorder, the initial 
objective is to reduce plasma ammonia [43] by removing protein from the diet [44]. In 
extreme cases, clinicians will prescribe dialysis and/or scavenging agents sodium 
benzoate, sodium phenylacetate, or sodium phenylbutyrate [45]. These three drugs work 
by incorporating waste nitrogen into compounds that have high renal clearance [46,47]. 
While patients are taking these drugs, they also remain on low-protein diets.  
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N-carbamylglutamate (NCG) effectively restores ureagenesis and reverses 
hyperammonemia in NAGS deficient patients and is the only specific treatment available 
for any urea cycle disorder.  NCG is a stable glutamic acid derivative that activates CPS1 
in the absence of NAG [30]. NCG has a lower affinity for CPS1, but is more effective 
than NAG since administered NAG is inactivated by acylases and does not reach the 
mitochondria [48]. 
NCG was first described as a result of Grisolia and Cohen’s experiments to uncover 
the mechanism for synthesis of citrulline from ornithine [5]. They showed that the 
combination of the enzyme system, ammonia, and NCG followed by addition of ornithine 
results in citrulline synthesis. As a result of these observations, they hypothesized that 
reaction involves two steps; the creation of NCG, and the fixation of ammonia [49,50]. 
However, further experiments failed to isolate any detectable amount of NCG from the 
liver. Instead, they isolated and characterized NAG from mammalian liver. The presence 
of NAG and high catalytic CPS1 activity indicated that it is the natural co-factor in CP 
synthesis [51]. Despite the failure to detect endogenous NCG, the fact that it is not 
degraded in the liver held promise as a treatment for hyperammonemia. A combination of 
NCG and arginine prior to giving rats a lethal dose of ammonia protected 100% of the 
rats, while NAG was relatively ineffective due to hydrolysis by acylaminoacid acylase. 
This was the first time showing rational basis for using NCG and a urea cycle intermediate 
in the treatment of hyperammonemia [52].  
The first case of NAGS deficiency and successful treatment with NCG was 
documented in 1982 [30]. Since Bachmann’s initial diagnosis and treatment, other cases 
of treating NAGS deficiency with NCG have been described [38,39,53-55]. NCG is sold 
 12 
 
and marketed by Orphan Europe under the name Carbaglu, and is approved by the FDA 
for the treatment of NAGS deficiency. Additionally, NCG has been used off-label for the 
treatment of CPS1 deficiency [56], propionic acidemia [57,58], and isovaleric acidemia 
[59]. 
Using Cell Culture to Study the Urea Cycle 
 
While cell lines are often useful in uncovering mechanisms involved in disease, 
they are not the best method to study urea cycle diseases. HepG2, a liver cell line derived 
from human hepatoblastoma, is a popular liver cell line. These cells continue to express 
genes related to cholesterol and triglyceride metabolism, which makes them a sufficient 
model to study some aspects of liver function [60]. However, these cells have lost other 
primary functions, including the ability to produce urea. HepG2 cells do not detoxify 
ammonia and produce urea when exposed to ammonium chloride and do not express 
detectable levels of urea cycle intermediates. This is due to the absence of OTC and ARGI 
expression [61,62]. These results were confirmed in our lab as well, demonstrating 
negligible levels of OTC and ARG1 in this cell line (see Appendix, Figure 29). One 
hypothesis to explain the lack of OTC and ARG1 is that this cell line is using excess 
carbamyl phosphate for pyrimidine synthesis [63] and excess arginine for polyamine 
production [64,65]. The synthesis of pyrimidines and polyamines would be beneficial to 
promote proliferation of these cancer cells. The lack of a complete urea cycle in this cell 
line shows that these cells are not adequate for the study of urea cycle function. A recent 
study showed that HepG2 cells could be stably transfected with OTC and ARG1, which 
results in an increase in ammonia detoxification [66]. Other hepatocellular carcinoma cell 
lines have shown a consistent down-regulation of CPS1 due to DNA methylation of the 
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promoter and first intron [67]. Therefore, the use of cell lines, especially those originating 
from cancer cells, is not suitable to study ureagenesis.  
IEC-6, a rat intestinal epithelial cell line, was first established and cultured 
successfully in 1979 [68]. Small intestinal epithelial cells are mitotically active and can 
divide in culture without being transformed into tumor cells. IEC-6 cells were derived 
from undifferentiated small intestinal crypt cells, and have normal morphology and 
karyotype. Despite this, this cell line does not produce citrulline. Our experiments 
revealed that IEC-6 only expresses trace of NAGS (Appendix, Figure 29), and thus is not 
suitable as a model to study citrulline production in the intestine.  
Mouse Models of Hyperammonemia 
Mouse Models of Urea Cycle Disorders 
The first mouse model for a urea cycle to be discovered and characterized was the 
model for OTC deficiency. There are two natural mouse models for OTC deficiency, 
which arose from spontaneous mutations in the X chromosome. The best characterized is 
the sparse fur (spf) mouse first reported in 1976 [69]. This mouse has a CàA mutation in 
exon 4 (H117N) which results in 10% normal enzyme activity associated with pH 
optimum shift[70]. The other OTC model, spfash (abnormal skin and hair) was reported in 
1974 [71] and is the result of a G à A missense mutation in exon 4 (R129H) which 
causes abnormal splicing and 5% normal enzyme activity [72]. Both models display the 
characteristics of OTC deficiency including elevated plasma ammonia, glutamine and 
urinary orotic acid, and decreased arginine and citrulline. Hemizygote males have an 
average lifespan of 42 days [73]. Recently, focus has been on using the spfash model in 
pre-clinical gene therapy studies [74].  
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The mouse model for CPS1 deficiency was created by deleting a portion of exon 
17 from the gene. The mutation in the gene abolishes all CPS1 activity in the liver of 
homozygotes. All Cps1-/- mice begin to experience hyperammonemia around 6 hours 
following birth, and die within 36 hours of birth. This model no longer exists [75].  
There are also multiple models for ASS deficiency. The first, described in 1994, 
has an engineered mutation in exon 4 which abolishes all ASS activity [76]. Homozygous 
ASS mice develop hyperammonemia about 10 hours post-birth and most die within 24 
hours. This model has also been used for gene therapy using an adenovirus vector that 
seems to be successful in restoring some ASS activity [77]. Two spontaneous mutations in 
the ASS gene have also been reported. These mice exhibit growth retardation, alopecia, 
lethargy, ataxia, and delayed cerebellar development associated with increased levels of 
citrulline and ammonia, similar to symptoms in patients. Treatment of these mice with 
sodium benzoate and arginine has been successful, resulting in normal brain development 
and survival to at least 6 weeks of age [78].  
The mouse model for ASL deficiency was created by deleting exons 8 and 9 of the 
gene, which decreases enzyme activity to about 4% of wild type. All ASL homozygote 
mice die within 48 hours post-birth and exhibit elevated ammonia, glutamine, citrulline, 
and argininosuccinic acid, and low arginine [79].  
Lastly, the ARG1 knockout mouse was created by replacing exon 4 with the gene 
encoding neomycin resistance, which completely abolishes all enzyme activity. Genotypic 
analysis revealed there is a non-Mendelian distribution of genotypes, with a significant 
deficit of ARG1 homozygotes. ARG1 homozygotes die within 10-14 days post-birth and 
exhibit hyperammonemia and increased arginine and decreased ornithine levels. The 
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authors of this study postulate that the ARG1 deficient mice survive for 10 days because 
during the neonatal stage, the enzyme ornithine aminotransferase (OAT) converts 
glutamate into ornithine. However, at approximately two weeks of age, intestinal OAT 
switches to produce glutamine, leaving ARG1 as the sole source of ornithine production. 
With no pathway to produce ornithine, the ARG1 mice are lacking a key metabolite in the 
urea cycle, resulting in hyperammonemia [80].  
Though mouse models for all the urea cycle disorders have been created and 
characterized, these mice either do not survive beyond the neonatal period, or do not 
reproduce. Therefore, it is difficult if not impossible to conduct comprehensive studies of 
hyperammonemia using these models.  
Inducing Hyperammonemia in Rodents 
In order to study hyperammonemia in rodents, several models have been 
developed which result in increased plasma ammonia levels. The simplest model involves 
feeding the rodent a standard diet supplemented with 20% ammonium acetate for 100 
days. This diet results in increased ammonia levels in the brain, liver, and muscle, a 2-fold 
increase in urea production, an increase in expression of glutamine synthase, glutamate 
dehydrogenase, and higher brain glutamine concentrations [81]. It appears as though the 
liver can adjust to this high-ammonia diet, as it increases urea production. This occurs 
without an increase of CPS1 or NAGS activity; however it is reported that the high-
ammonia diet increases the mitochondrial content of NAG [82]. There were no 
neurobehavioral changes in these animals and levels of brain glutamate and aspartate were 
not significantly affected.  Therefore, simply supplementing mice with high-ammonia 
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diets is not sufficient to significantly alter the brain chemistry in a way that mimics a 
hyperammonemic crisis.  
There are two surgical methods to induce hyperammonemia in rodents. The first is 
by creating a portocaval shunt. In this case, portal blood carrying ammonia is no longer 
processed by the liver, instead this blood enters the systemic circulation, resulting in liver 
atrophy [83]. This model leads to chronic hyperammonemia, which results in neurological 
symptoms such as abnormal circadian rhythms and sleep patterns [84] and postural 
abnormalities [85] that are associated with increased brain ammonia/glutamine and 
neurotransmitter function and altered ratios of aromatic/branched chain amino acids [83], 
When rats with a portocaval shunt are given an ammonia challenge, they develop lethargy, 
myoclonic twitching, and coma, whereas normal rats given an ammonia challenge develop 
some mild neurological symptoms but eventually recover. [86-88].  
Chronic liver injury can also be induced with bile duct ligation, which induces a 
reproducible model of biliary cirrhosis, an autoimmune disease that causes bile buildup in 
the liver [83]. Rodents with a bile duct ligation develop hyperammonemia but only low-
grade encephalopathy with decreased locomotor function. These rodents only develop 
hepatic encephalopathy with neurological symptoms following the ingestion of 
ammonium salts [89-91].  
Rationale for the Creation of the Nags-/- Mouse 
 
As mentioned, the usefulness of mice with urea cycle defects has been rather limited 
due to neonatal lethality and difficulties in rescue by biochemical interventions for any 
significant length of time. Rodent models for inducible hyperammonemia involve 
extensive surgery, cause unnecessary stress to the rodent and are not reversible. The 
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availability of a mouse with a severe urea cycle defect that could be salvaged by a simple 
biochemical intervention would enhance research into various aspects of 
hyperammonemia and ureagenesis. Since NAGS deficiency is the only urea cycle disorder 
with a biochemical cure, we hypothesized that we could create a NAGS knockout mouse, 
and rescue the homozygous pups (Nags-/-) with NCG, which would allow them to survive 
past the neonatal period into adulthood and reproduce. We reasoned that if such a murine 
model could be reared to reproductive age, a large number of homozygous mice could be 
produced and studied. Furthermore, hyperammonemia could be induced and suppressed as 
necessary by manipulating the biochemical rescue allowing studies during, and off 
treatment. The creation of this mouse represents the first “clean”, inducible, salvageable 
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Introduction 
In mammals, nitrogen waste in the form of neurotoxic ammonia is converted in the 
liver to urea, which is then excreted in the urine [14]. Ureagenesis requires at least eight 
proteins and is initiated in the mitochondria via the activation of carbamyl phosphate 
synthetase 1 (CPS1) by N-acetyl-L-glutamate (NAG) [9]. NAG is produced by NAG 
synthase (NAGS) from L-glutamate and acetyl-CoA [6]. Inherited or acquired deficiency 
of NAGS catalytic activity causes a functional block in ureagenesis, due to the 
corresponding reduction or abolishment of CPS1 activity, leading to the accumulation of 
ammonia in the blood [30,92]. The clinical presentation and biochemical features of 
NAGS deficiency are indistinguishable from those of CPS1 deficiency and include 
elevated plasma glutamine, reduced citrulline, and normal levels of urinary orotic acid and 
orotidine [43].  
Mouse models of complete enzyme deficiency and hyperammonemia have been 
created for each of the urea cycle enzymes with the exception of NAGS 
[43,69,75,79,80,93-95]. However, their usefulness for research has been rather limited due 
to neonatal lethality and difficulties in rescue by biochemical interventions for any 
significant length of time. Among these models, the one produced by Schofield et al. [75] 
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for complete CPS1 deficiency (homozygous knockout) proved to be lethal within one day 
after birth. The availability of a mouse with a severe urea cycle defect that could be 
salvaged by a biochemical intervention would enhance research into various aspects of 
hyperammonemia and ureagenesis. We reasoned that if such a murine model could be 
reared to reproductive age, a large number of homozygous mice could be produced and 
studied. Furthermore, hyperammonemia could be induced and suppressed at will by 
manipulating the biochemical rescue allowing studies during, and off acute disease.  
Unlike all other urea cycle disorders, NAGS deficiency in humans is amenable to 
effective treatment with N-carbamyl-L-glutamate (NCG) [54], a functional analog of 
NAG that has been shown to be resistant to in vivo degradation. There is good evidence 
that this molecule reaches the liver, enters the mitochondria and activates CPS1 in vitro 
and in vivo [9,52]. We therefore surmised, that if a NAGS knockout mouse could be 
created, the homozygous pups (Nags-/-) could potentially be rescued by treatment with 
NCG allowing them to survive beyond the neonatal period and perhaps even to adulthood. 
We document herein, the successful creation of the first salvageable mouse model of 
a urea cycle enzyme deficiency. We demonstrate that the Nags-/- mouse, which shows 
neonatal lethality similar to Cps1-/- mice, can be rescued by combinational therapy of 
NCG and L-citrulline (Cit), and consequently reach adulthood and reproduce to create 
litters of exclusive Nags-/- animals. We describe the procedure for rescue of Nags-/- mice, 
characterization of this new hyperammonemia mouse model, and show that the animal 
wellbeing depends on continued supplementation of NCG with the addition of Cit.  
 20 
 
Materials and Methods 
Generation of the NAGS knockout mouse 
The trans-NIH Knock-Out Mouse Project (KOMP, www.komp.org), an NIH 
supported strain repository at the University of California Davis, was successful in 
transferring null alleles for Nags in two C57BL/6 embryonic stem cell lines and cryo-
achieving germ line transfer embryos (C57BL/6N-Nagstm1(KOMP)Vlcg). The strategy used 
for generating the ES cell clones with deletion of the entire gene is illustrated in Figure 5. 
Homologous recombination allows the entire Nags gene to be replaced with the ZEN-UB1 
cassette within the bacterial vector, containing the coding sequences for lacZ and 
neomycin resistance genes. NIH grants to Velocigene at Regeneron Inc. (U01HG004085) 
and the CSD Consortium (U01HG004080) funded the generation of gene-targeted ES 
cells for 8500 genes in the KOMP Program which are archived and distributed by the 
KOMP Repository at UC Davis and CHORI (U42RR024244)[96]. The KOMP Repository 
provided us four C57BL/6N-Nagstm1(KOMP)Vlcg heterozygous mice from the cryo-archive. 
These mice (Nags+/-) were crossed with wild type Swiss Webster (Charles River 
Laboratories). The resulting first generation of heterozygous was crossed to obtain 
homozygous mice (Nags-/-). Of these homozygous animals, those that were reared to 





Figure 5. Strategy for deletion of the Nags gene.   
Diagram of the Nags gene (top) and the large BAC-based targeting vector (bottom). 
Homologous recombination allows the entire Nags gene to be replaced with the ZEN-UB1 
cassette, which contains the coding sequences for LacZ and neomycin resistance genes. 
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Animal Care and Husbandry 
Mice were cared for in accordance with the guidelines set forth by the American 
Association for Accreditation of Laboratory Animal Care and all the studies were 
approved and supervised by the Children’s National Medical Center Institutional Animal 
Care and Use Committee (protocol number 247-09-11). Mice were cared and bred in the 
Research Animal Facility (barrier facility) under controlled temperature (68°F) and a 12 
hours light/dark period. They were fed Harlan Tecklad irradiated chow (2018) and 
sterilized water. 
Genotyping and Identification 
Newborn pups were identified using tattoo patterns (Ketchum Manufacturing Inc.). 
Genomic DNA was isolated from tail biopsies with the Puregene Core Kit A (Qiagen). 
Figure 6A illustrates the strategy used to genotype the pups using the PromegaGoTaq 
system. The strategy involves a three-primer PCR assay. Primer A (5’-
ACTGTCAGAGAAAAGCGCTCAGGA-3’) corresponds to a region in the 5’ end of the 
Nags gene. Primer B (5’-ACATACACTTCATTCTCAGTATTGTTTTGCC-3’) 
corresponds to a region within the neomycin selection cassette in the knockout allele. 
Primer C (5’- CTGTTTTTCAGACACATCAGATCCCG-3’) is a “common” primer 
corresponding to a region downstream of the Nags gene. The product of Primer A and 
Primer C is a 1707 bp amplicon, which corresponds to the wild type allele. The 
combination of Primer B and Primer C produces a 1082 bp amplicon and corresponds to 
the knockout allele. Following one cycle of denaturation at 95 °C for 5 min, a total of 33 
cycles were performed each consisting of 95 °C for 15 sec, 60 °C for 20 sec, and 72 °C for 
1 minute. Both alleles were separated by electrophoresis in a 1% agarose gel, and a 
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depiction of this gel with patterns for wild type, heterozygous, and knockout alleles is 
show in Figure 6B, with a 1 Kb+ ladder as a reference (Invitrogen). Wild type and 
heterozygote control DNA were derived from tissue collected from original stock mice 








Figure 6. Strategy for genotyping.  
(A) The combination of primers A and B and A and C amplifies a 1707 bp fragment from 
the normal Nags allele and a 1082 bp fragment from the targeted Nags allele respectively. 
(B) PCR products that indicate the animals’ genotype. Genotype of each sample is shown 








Frozen mouse liver was pulverized in liquid nitrogen. Small intestine epithelial 
cells were isolated according to Evans et al.[97]. Cells were lysed in RIPA buffer (Sigma) 
containing PhosSTOP protease inhibitor tablets (Roche). Protein concentrations were 
quantified using Protein Assay dye reagent (Bio-Rad) according to manufacturer’s 
instructions. Proteins in cell lysate were resolved on 10% SDS-polyacrylamide gel, 
transferred to a nitrocellulose membrane, and blocked in Starting Block (Thermo 
Scientific) with 0.5% Surfact-Amps 20 (Thermo Scientific). Ten micrograms of total liver 
protein and 60 µg of small intestinal epithelial protein were used to probe with NAGS 
antibody (1:5000 dilution of primary rabbit anti-NAGS antibody raised against 
recombinant mouse NAGS) and HRP-conjugated donkey anti-rabbit secondary antibody 
(1:50,000) (Pierce). CPS1 was probed in 1 µg of total liver protein and 10 µg small 
intestinal epithelial protein using rabbit anti-CPS1 primary antibody (AbCam 1:5000) and 
HRP-conjugated donkey anti-rabbit secondary antibody (Pierce 1:10,000). OTC was 
probed in 1 µg of total liver protein and 10 µg small intestinal epithelial protein using 
rabbit primary antibody raised against recombinant ornithine transcarbamylase (OTC) 
(1:5000) and HRP-conjugated donkey anti-rabbit secondary antibody (Pierce 1:10,000). 
Protein bands were visualized using Super Signal West Pico kit (Pierce). Tubulin, probed 
with the anti-tubulin primary antibody (Abcam) at 1:200 dilution followed by goat-anti-
rabbit (1:5,000) (Abcam), was used as a loading control. The density of NAGS, CPS1, 
OTC, and tubulin bands were quantified using a GS-800 calibrated densitometer (Bio-rad) 
and analyzed with Quantity One software, version 4.5.2 (Bio-rad). NAGS, CPS1, and 
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OTC bands were normalized against tubulin density and then expressed as a percentage of 
Wild type control.   
Chemical Rescue of Nags-/- mice 
Heterozygote breeding pairs were given water supplemented with NCG (1.0 g/L) 
(Orphan Europe, Paris) and L-citrulline (1.0 g/L) (VWR). Nags-/- pups were given daily 
intraperitoneal injections of NCG and citrulline dissolved in Lactated Ringer’s solution 
starting at birth and continuing until weaning. The initial dose was 250 mg/kg/day for 
NCG and 1000 mg/kg/day for Cit, and as the animals grew, the dose was tapered to 
approximately 130 mg/kg/day NCG and 525 mg/kg/day Cit. After weaning (typically 21 
days), Nags-/- mice were maintained on water supplemented with NCG and Cit (1.0 g/l 
each). 
Plasma Ammonia and Amino Acid Measurements 
 Plasma was collected into a pre-chilled heparinized syringe from anesthetized mice 
via heart puncture. The sample was transferred immediately to a pre-chilled heparinized 
tube and centrifuged at 4oC for 10 min to separate the plasma. The plasma was transferred 
to cryogenic tubes and immediately frozen in dry ice and stored at -80oC until analysis 
within 48 hr. Plasma ammonia measurements were performed on a Dade Behring 
Dimension RXL clinical chemistry system (Dade Behring, Newark, DE), using an 
adaptation of the glutamate dehydrogenase enzymatic method of van Anken and Shiphorst 
[98] which substitutes NADPH for NADH, eliminating interference from other NADH-
consuming reactions. The reaction was carried out in a Dimension® Ammonia (AMON) 
Flex reagent cartridge (K863840; Dade Behring, Newark, DE). The disappearance of 
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NADPH was measured by spectrophotometry.  
Amino acid concentrations in plasma were measured by ion-exchange 
chromatography on a Biochrom amino acid analyzer. Plasma proteins were first 
precipitated with an equal volume of 7% sulfosalicylic acid and centrifuged for 10 
minutes at 13200 rpm. Next, 5 µL of 2.5 N LiOH and 10 µL stock internal standard (S-2-
aminoethyl-L-cysteine hydrochloride) were added to 100 µL of plasma supernatant before 
injection into the analyzer. 
Liver Function 
Plasma was collected as described above and sent to the Mouse Metabolic 
Phenotyping Core at Yale University. Plasma levels of alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), alkaline phosphatase (ALP), and blood urea nitrogen 
(BUN) were conducted on the Roche COBAS Mira Plus automated chemistry analyzer. 
Statistical Analysis 
All statistical analyses were performed using Prism software, version 5 (GraphPad, 
San Diego, CA). The minimal level of confidence at which experimental results were 
considered significant was p<0.05. Statistical significance of differences in weight gain 
among the strains and between their amino acid levels was determined by a two-way 
ANOVA with Bonferroni posttest analysis. Statistical significance of differences in 
ammonia concentrations was determined by one-way ANOVA with Bonferroni posttest 
analysis. Analysis of genotype segregation from heterozygous matings was performed 
using a Chi-squared test. In all cases, data is presented as the mean ±	 SEM. In all figures, 




Breeding of Mice 
C57Bl/6N mice, heterozygous for the disrupted Nags allele (Nags+/-) were crossed 
to obtain homozygote animals. After several litters, we observed that the average litter 
size was 6.5 pups, but overall survival rate of the pups was only 45% in these crossings, as 
mothers were not taking care of their pups. We also observed an increased incidence of 
birth defects due, possibly, to the inbreeding of the strain used to develop these mice. 
Therefore, Nags+/-C57BL/6N mice were subsequently crossed with wild-type mice of the 
Swiss-Webster strain to increase the genetic heterogeneity. SW;B6-Nagstm1(KOMP)Vlcg 
heterozygous females were able to produce larger litters and maintain them, with an 
average litter size of 7.9 pups and overall survival rate of 87%, thus markedly reducing 
confounding factors with respect to survival and health of the pups (Figure 7A and 7B). 
No birth defects were observed using SW;B6-Nagstm1(KOMP)Vlcg heterozygous mice for 
crossing. Pups were genotyped within 48 hours of birth by PCR (Figure 6A and 6B).  
NAGS deficiency is the most rare urea cycle disorder, with only 34 reported 
patients from 28 families worldwide. Our initial hypothesis was that NAGS deficiency 
could lead to in utero lethality, resulting in a lower number of children born with this 
disease. In order to determine if NAGS deficiency causes in utero lethality, the genotypes 
of offspring from 11 liters (127 pups) of heterozygote crosses were analyzed. This 




Figure 7. SW;B6-Nagstm1(KOMP)Vlcg heterozygous females produce larger litters (A) 
and successfully maintain them better (B) compared to inbred Nags+/-C57BL/6N 
mice.  
Nags+/-C57BL/6N were mated with Wild Type Swiss Webster mice to produce a hybrid 
strain. Nags+/-C57BL/6N  n= 82 litters; SW;B6-Nags n= 60 litters. Statistical significance 
















































expected Mendelian inheritance (1:2:1) (Χ2= 0.890, df=2, p=0.6409) indicating 
improbable in utero lethality of Nags-/- mice when the mothers are maintained on NCG 
and Cit supplementation in the drinking water (Table 1A). Based on this observation, it 
was hypothesized that the NCG/cit supplementation during the pregnancy benefits the 
Nags-/- fetuses, resulting in normal in utero health and development. In order to test this 
hypothesis, heterozygotes were mated without NCG/cit supplementation to the pregnant 
females. Collection of pups was performed prior to birth (E14) to prevent the loss of pups 
following birth. Analysis of the offspring from 4 litters (29 pups) from these crosses 
revealed that the genotypes were still consistent with the expected Mendelian inheritance 
pattern of 1:2:1 (Χ2= 3.897, df=2 p=0.1425) (Table 1B). Therefore, we can conclude that 
Nags-/- mice remain healthy in utero, due to the mother’s circulatory system detoxifying 
excess ammonia produced by the fetuses. It is only after birth that the Nags-/- mice require 
supplementation to promote ureagenesis. Additionally, in utero lethality is not a 




















Table 1. Progeny from heterozygous mating.  
(A) Progeny of Nags+/- mice where mother was supplemented with NCG during 
pregnancy. Analysis was done on 127 mice from 11 litters (χ2= 0.890 df=2 p=0.6409). (B) 
Progeny of Nags+/- mice were mother was not supplemented with NCG during pregnancy. 
Analysis was done on 29 pups from 4 litters (χ2= 3.897, df=2 p=0.1425).  
Genotype	   Observed	  	   Expected	   P	  value	  
Nags+/+	   32	   31.75	   0.6409	  
Nags+/-­‐	   59	   63.5	   	  
Nags-­‐/-­‐	   36	   31.75	   	  
	   	   	   	  
Total	   127	   127	   	  
Genotype	   Observed	  	   Expected	   P	  value	  
Nags+/+	   3	   7.25	   0.1425	  
Nags+/-­‐	   19	   14.5	    
Nags-­‐/-­‐	   7	   7.25	    
    





 Analysis of the NAGS protein in the liver and small intestine was performed by 
Western blotting. The analysis confirmed the genotypes, showing absence of NAGS in 
these organs in Nags-/- mice. The abundance of NAGS protein in the liver and small 
intestine of Nags+/- mice ranged between 50-70% and 15-25% respectively, of Nags+/+ 
littermates (Figure 8). This confirms that Nags disruption abolishes its expression in both 
the liver and small intestine. Expression of the remaining mitochondrial urea cycle 
enzymes, CPS1 and OTC, in both the liver and small intestine were similar in Nags-/-, 
Nags+/- and Nags+/+ littermates (Figure 9).  
Biochemical Rescue of Nags-/- Mice 
Heterozygote breeding pairs were supplemented with NCG (1.0 g/l) and Cit (1.0 
g/l) in the drinking water. This ensured that Nags-/- fetuses received NCG and Cit during 
in utero development. However, supplementation of heterozygous pregnant females with 
NCG and cit proved to be insufficient to rescue the newborn Nags-/- pups and they died 
within 24-48 hours of birth if no other intervention was initiated (Figure 9). This 
suggested that insufficient NCG and/or Cit was transferred to the pups via the mother’s 
milk to mitigate the enzyme deficiency and resulting hyperammonemia. To improve 
delivery of the rescue chemicals, homozygous pups were administered by intra-peritoneal 
injection of NCG and Cit dissolved in Lactated Ringer’s solution within a few hours 
following birth and continuing once every day until weaning. The initial dose was 250 
mg/kg/day NCG and 1000 mg/kg/day Cit, and as the animals grew, the dose was tapered 
to approximately 130 mg/kg/day NCG and 525 mg/kg/day Cit. The dosage for mice was 





Figure 8. NAGS is absent in the liver (A) and small intestine (B) of Nags-/- mice.  
10 µg of liver protein and 60 µg of small intestine protein were loaded in each lane to 
detect expression of NAGS protein in Nags+/+, Nags+/-, and Nags-/- mice. Densitometry 
analyses of the blots are shown. Data were normalized to the tubulin protein and then 
expressed as a fraction of the respective protein in the wild type (Nags+/+) mice. 





Figure 9. Western blots of CPS1 and OTC in liver (A) and small intestine (B).  
1 µg of liver protein and (B) 20 µg of small intestine protein were loaded in each lane to 
detect expression of CPS1 and OTC proteins in Nags +/+ , Nags+/-, and Nags-/- mice. 
Corresponding densitometry analyses of the blots are shown. Data were normalized to the 
tubulin protein and then expressed as a fraction of the respective protein in the wild type 
(Nags+/+) mice. Immunoblots represent one blot that is representative of the results 





 The addition of Cit to the treatment regimen enhanced survival of the mice. 
Without Cit, approximately 50% of the Nags-/- pups died before weaning, while the NCG 
plus Cit supplement increased survival to 85% (Figure 10). After weaning (typically 21 
days), homozygous pups were switched to supplementation with NCG plus Cit in the 
drinking water, which had proved sufficient for survival to adulthood and reproduction. 
Our decision to supplement with citrulline was based on studies describing the ornithine 
aminotransferase (OAT) knockout mouse [99]. In neonatal mice, OAT is responsible for 
producing ornithine from glutamate. The deletion of OAT results in hypoornithinaemia 
and lethality, which is rescuable by arginine supplementation. Since urea cycle patients 
often display low plasma arginine, we decided to supplement these mice with citrulline, as 
it is an immediate precursor for arginine.  
In order to investigate the dependency on NCG plus Cit in the adult period, 6-
week-old male and female mice were given water with various combinations of 
supplements. Mice on water alone died within 24 hours, and mice drinking water with 
only Cit supplementation died within 24-48 hours (Figure 11). Mice given water with 
NCG only or NCG/Cit were monitored for survival over a 30-day period. At the end of 14 
days, 50% of the mice on NCG alone were alive, whereas 89% of the mice on NCG/Cit 
supplementation were alive (Figure 11). These results indicate that while Cit is not 
absolutely required in the adult period, it does serve a beneficial role in overall health and 
survival of the Nags-/- mice. Based on the concentration of NCG and Cit that was 
provided, a 25 g mouse would consume approximately 150 mg/kg/day of NCG and Cit. 
This dosage is within the range of the standard dosage recommended for patients. 
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Appearance of Nags-/- Mice 
At birth, Nags-/- mice are indistinguishable from their heterozygous and wild type 
littermates. As Nags-/- neonates age, a subtle phenotype arises. Nags-/- mice have less fur 
compared to their Nags+/- littermates (Figure 12). However, this phenotype is not present 
in every homozygote, and is more obvious in mice with white fur. Some homozygotes 
may develop a full coat of fur as they age. As a result, distinguishing homozygotes by fur 
pattern is not reliable. Fur abnormalities are also seen in the two partial OTC deficiency 
mouse models, OTCspf and OTCspf-ash [69,71] suggesting perhaps that this phenotype is 
related to Cit or arginine deficiency as proposed previously [100]. In order to determine if 
Nags-/- mice have growth defects, litters were weighed daily until weaning. Overall, the 
weight of rescued Nags-/- mice was lower (p<0.01) during the pre-weaning period 







Figure 10. Biochemical rescue of Nags-/- pups.  
(A) Kaplan-Meier survival curves of pups on and off NCG ± Cit treatment. Nags-/- pups 
were given either no supplementation or intra-peritoneal injections of NCG or NCG/cit 
daily starting at birth and assessed for survival.  
  





















Figure 11. Biochemical rescue of Nags-/- mice after weaning.  
Kaplan-Meier survival curves of six-week-old mice were given different supplements in 
water (NCG, Cit, or NCG/Cit).  
  
























Figure 12. Phenotype of Nags-/- mice.  





Figure 13. Growth of Nags-/- mice. 
 Nags+/+, Nags+/-, and Nags-/- mice were weighed daily during the pre-weaning period. 
Weight differences were analyzed using a two-way ANOVA followed by a Bonferroni 
post-test.  
 

























Metabolic Phenotype of Nags-/- Mice 
NCG and Cit were withdrawn from 2-month-old Nags-/- mice in the evening prior 
to the dark period. Behavior related to hyperammonemia was assessed according to the 
scoring system outlined in Ye, X et al [101]. Mice were sacrificed when they showed 
symptoms of severe hyperammonemia (lethargy, seizures, lying on side, decerebrate 
posture). All Nags-/- mice deprived of NCG and Cit supplements developed signs of 
severe hyperammonemia, however time of onset of symptoms was variable ranging from 
10 to 28 hours. Plasma ammonia levels did not differ between Nags+/+, Nags+/-, and Nags-/- 
littermates when NCG and NCG/Cit treatments were given. However, Nags-/- mice 
deprived of NCG/Cit supplements displayed plasma ammonia levels in the range of 1000-
3000 µmol/L (approximately 10-fold higher than their littermates, p<0.0001), confirming 
that the development of severe hyperammonemia following treatment withdrawal is a 
characteristic of these mice and can be measured using methods similar to human subjects 
(Figure 14). 
Plasma was also analyzed to determine the effect of NCG plus Cit supplementation on 
amino acid concentrations. Nags+/+, Nags+/-, and Nags-/- mice given NCG/Cit 
supplementation had similar plasma amino acid levels, except for higher plasma glutamate 
in the Nags-/- mice (p<0.0001) (Figure 15A). Hyperammonemic (NCG/Cit deprived) 
Nags-/- mice exhibited lower concentrations of plasma arginine, citrulline, ornithine, 
proline (Figure 15A) and alanine (p<0.0001) (Figure 15C), and elevated glutamine (p 
<0.0001), glutamate (Figure 15A), and lysine (p <0.0001), compared to healthy controls. 
(Figure 15C). All other amino acids (Figure 15C), including branched chain amino acids 







Figure 14. Ammonia levels of Nags-/- mice.  
(A) Plasma ammonia levels in Nags mice were measured following withdrawal of NCG 
and citrulline from Nags-/- mice.  Plasma was collected when Nags-/- mice showed 
symptoms of severe hyperammonemia (lethargy, seizures, lying on side, decerebrate 
posture). Nags+/+, Nags+/-, and supplemented Nags-/- mice were used as controls. Data 
























Figure 15. Amino acid panel of Nags-/- mice.  
Plasma concentrations of (A) urea cycle related amino acids, (B) branched chain amino 
acids, (C) other amino acids. Plasma was collected when Nags-/- mice showed symptoms 
of severe hyperammonemia (lethargy, seizures, lying on side, decerebrate posture). 
Nags+/+, Nags+/-, and supplemented Nags-/- mice were used as controls. Graphs show mean 
±	 SEM. Statistical significance was analyzed using a two-way ANOVA followed with 
Bonferroni post-test (p<0.0001,****), comparing to wild type mice. Nags+/+ n=12, Nags+/- 




Lastly, it was of interest to establish whether NAGS deficiency contributes to liver 
damage since liver damage has been reported in urea cycle disorders, including liver 
necrosis and abnormal mitochondria in ASS deficiency [102], mitochondrial 
abnormalities in OTC and CPS1 deficiency [103, 104], and fibrosis in females with partial 
OTC deficiency. As an indicator of liver damage, plasma aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and blood urea 
nitrogen (BUN) were measured.  AST, ALT, and ALP are liver enzymes and their 
presence in the plasma is an indication of hepatocellular damage. BUN is a measurement 
of nitrogen levels in the blood; an elevated BUN can indicate kidney damage if the kidney 
is not excreting urea, while a decreased BUN may indicate liver damage or a block in the 
urea cycle (not producing urea). We compared the levels of these four indicators in 
healthy, 6-week-old Nags-/- mice to that of wild type litter mates. For all four, levels are 
identical suggesting that Nags-/- deficiency is likely not contributing to liver damage in 





Figure 16. Liver function tests in Wild Type and Nags-/- mice.  
Plasma levels of alanine aminotransferase (A), aspartate aminotransferase (B), alkaline 
phosphatase (C), and blood urea nitrogen (D) were analyzed on a Roche COBAS Mira 
















































Using gene transfer techniques of null alleles available through KOMP, we 
produced a knockout mouse model of hyperammonemia due to complete NAGS 
deficiency. Genotypic analysis of the progeny from mating between Nags+/- mice revealed 
Mendelian segregation of the Nags null allele, thus excluding increased embryonic 
lethality in this model. Therefore, a potential role of NAGS in fetal development [32] 
seems unlikely to explain the extreme rarity of the NAGS deficiency in humans. Nags-/- 
mice lack NAGS protein in both the liver and small intestine (Figure 8). Thus, when this 
gene is absent, ureagenesis and de novo citrulline and arginine production do not occur 
resulting in neonatal death of Nags-/- pups unless they are rescued (Figure 10). 
Fortunately, Nags-/- mice could be rescued with a combination of NCG and Cit 
administration, where we obtained an 85% success rate in rearing homozygous pups to 
weaning and subsequently to reproduction. Since Nags+/+ and Nags+/- pups did not die 
following injections with NCG/Cit, we believe that the 15% loss in the neonatal period for 
Nags-/- pups relates to NAGS deficiency in spite of rescue therapy. It is possible, that the 
stress of daily intra-peritoneal injections could have contributed to this loss. A portion of 
this 15% loss includes smaller newborn mice that died within 10-15 days after birth. 
Whether larger dosages of NCG and citrulline mitigates this low early lethality in all or a 
portion of these mice requires further testing.  
The requirement for NCG/Cit supplementation for survival of Nags-/- mice 
continues into adulthood, since they become hyperammonemic within hours following 
withdrawal of NCG/Cit from the drinking water. If not supplemented with NCG/Cit, the 
Nags-/- mice experience a 10-fold increase in ammonia levels within one to two days 
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(Figure 14) similar to the phenotype reported in other mouse models with complete 
deficiency of other urea cycle genes that cannot be salvaged [75,78-80,105], as well as the 
ornithine aminotransferase (OAT) knockout mouse when not supplemented with arginine 
during the neonatal period [99]. Although the addition of Cit does not seem to be 
absolutely essential for survival of the Nags-/- mice, it appears to serve a beneficial role, as 
50% of adult Nags-/- mice treated with only NCG in drinking water die within 14 days 
(Figure 11), compared to only 11% death if treated with NCG/Cit. Among the tests that 
were performed, the only significant difference found between Nags-/- mice on NCG vs. 
NCG/Cit is elevated plasma glutamine level in mice supplemented with NCG only (Figure 
15A), suggesting some increase in nitrogen load in these animals [106,107]. However, 
these mice did not display reduced plasma arginine or Cit, nor did they manifest 
hyperammonemia when tested randomly (Figure 14). Although arginine is a semi-
essential amino acid, it is required for biosynthesis of creatine, ornithine, glutamine, 
proline, and polyamines [108]. Arginine also serves a role in signaling functions, acting as 
the substrate for nitric oxide production [108] and in wound healing [109,110] and thus 
supplementation is recommended after physical stress such as post-surgery or trauma 
[111,112].  
In humans, NCG is the standard treatment for NAGS deficient patients 
[38,55,69,75,79,80,93-95,113]. We chose a regimen of NCG and Cit based on a study by 
Kim et al. [52,75], where an intra-peritoneal injection of NCG and arginine protected rats 
against lethal doses of ammonia. We adapted the dosage plan based on information on 
patient dosages [32,54]. Additionally, in a mouse model of OAT deficiency, arginine 
injections every 12 hours over the newborn period were necessary to compensate for a 
 49 
 
neonatal arginine deficiency [99]. We believed that Cit would be more efficient in this 
regard since arginine is rapidly degraded in the liver as a result of a high arginase activity 
[96,108] while citrulline bypasses the liver and is converted to arginine by the kidneys 
[27].  
We have evidence suggesting that adult Nags-/- mice exhibiting early signs of 
hyperammonemia can be rescued with an intra-peritoneal injection of NCG/Cit (data not 
shown). This observation suggests that their hyperammonemia could be reversed upon 
early intervention, which should allow for more controlled studies of the recovery of the 
brain from hyperammonemia. The Nags-/- mouse represents the first mouse model in 
which hyperammonemia can be prevented by chemical intervention and induced with the 
removal of the chemical. The creation of this mouse will allow for the study of global 
effects of hyperammonemia, in particular the effects on the central nervous system. It 
should also prove useful as a model for the study of liver gene therapy in complete urea 
cycle disorders, which would be challenging in animals with complete enzyme deficiency 
that die during the neonatal period. 
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Chapter 3: Use of a Home Cage Monitoring System to Define 





Hyperammonemia is a metabolic disease state characterized by the excess of 
ammonia in blood. Ammonia is a source of nitrogenous waste that results from the 
catabolism of dietary and body proteins. Hyperammonemia occurs when there is an 
impaired capacity to detoxify ammonia; for example, in the case of urea cycle disorders, 
organic acidemias, cirrhosis, certain surgeries, Reye syndrome, drug overdose, or 
chemotherapy [1,114]. Hyperammonemia leads to clinical symptoms such as loss of 
appetite, vomiting, lethargy, seizures, neurological damage, coma, and potentially death if 
untreated [32,115]. Current treatments for hyperammonemia include dialysis [116], 
ammonia scavenging drugs, and complete removal of protein from the diet [10].  
 Recently we described the creation of a NAGS deficient mouse (Nags-/-) a novel 
model of hyperammonemia [117]. Until the creation of this mouse, all other mouse 
models of urea cycle disorders have been unsuccessful in studying hyperammonemia due 
to neonatal lethality [43]. However, NAGS deficiency symptoms can be eliminated with 
the administration of the FDA approved compound,  N-carbamyl-L-glutamate (NCG), a 
functional analog of NAG. Thus, the Nags-/- mouse is treated with NCG starting at birth 
where it survives to adulthood and reproduces. The availability of this mouse model with 
a severe urea cycle defect capable of being salvaged by a biochemical intervention has the 
potential to enhance research into various aspects of hyperammonemia and ureagenesis.  
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Early detection and therapy of hyperammonemia is important, as it decreases the 
risk of permanent brain damage. However, the earliest symptoms in mice are difficult to 
detect. In our previous study [117], we used a scoring system developed by Ye, et al 
[101], and sacrificed mice when they showed signs of severe hyperammonemia including 
lethargy, decerebrate posture, lying on their side, and seizures. The ability to define a 
behavioral biomarker indicative of early hyperammonemia would make possible the 
investigation of early neurological effects of hyperammonemia, and how the neurological 
effects relate to clinical symptoms observed in patients. Moreover, early detection of 
clinical hyperammonemia in this mouse model would allow for testing of interventions to 
treat hyperammonemia without resorting to death as an endpoint. In this current study, 
two activity-monitoring systems were employed to analyze the behavior of Nags-/- mice 
during a healthy, treated state, and during hyperammonemia following the removal of the 
rescue chemicals, NCG and Cit.   
 
Materials and Methods 
Animal Husbandry 
Animals were housed at Children's National Medical Center and the Veterans 
Affairs Animal Research Facility and all protocols were approved by The Children’s 
National Medical Center and V.A. IACUC, Washington, DC. Mice were checked daily for 
signs of distress and were maintained on a 12:12-h light–dark cycle in a low-stress 
environment (22 °C, 50 % humidity and low noise) and given food and water ad libitum. 
The creation of the Nags-/- has been previously described[117].  Nags-/- pups were 
given daily intraperitoneal injections of NCG and Cit dissolved in Ringer’s lactate 
solution starting at birth and continuing until weaning. The initial dose was 250 
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mg/kg/day for NCG and 1000 mg/kg/day for Cit, and as the animals grew, the dose was 
tapered to approximately 130 mg/kg/day NCG and 525 mg/kg/day Cit. After weaning 
(typically 21 days), Nags-/- mice were maintained on water supplemented with NCG and 
Cit (1.0 g/l each). For the purposes of these studies, wild type mice were given NCG/cit 
supplementation for a 2-week period before the experiments were conducted. 
Voluntary Wheel 
Seven Nags-/- and 8 wild type littermate mice of 6 weeks of age were housed 
individually in cages equipped with a running wheel. Wheel running activity was 
monitored by an on-line PC connected to the Minimitter Running Wheel activity system 
via a magnetic switch on the wheels. This system consists of QA-4 activity input modules, 
DP-24 dataports and Vital View data acquisition system (MiniMitter Company, Inc. 
Sunriver OR vers. 4.1) [118-120]. Wheel revolutions were collected continuously and 
binned into 60-minute intervals. Mice were allowed to acclimate to the system for 24 
hours prior to data collection. Data was collected for 24 hours beginning at 10:00 AM, 
while mice were supplemented with NCG/Cit; after the initial 24-hour period, NCG/Cit 
supplementation was removed (at 10:00 AM) and data was collected for another 24 hours. 
Based on a wheel with a 14.13-inch circumference, one wheel revolution is equal to 0.36 
meters. The number of wheel turns per hour was multiplied by 0.36 to determine distance 
in meters run per hour.  
Home Cage Monitoring 
We used the Home Cage Scan system from CleverSys [121-125] consisting of 4 
cameras simultaneously monitoring 4 mice individually housed in separate cages on a 
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12:12 light: dark cycle. The cage environment was lit by white lights from 6 AM to 6 PM 
and infrared lights from 6 PM to 6 AM. The computer software allows the researcher to 
calibrate the cage, providing software with information about the cage environment such 
as the top/bottom of cage, height of bedding, placement of drinking spout, and food bin 
areas. The software then uses this information to recognize the animal and behavior in 
durations greater than 6 frames (30 frames/sec).  
Eight 6-week-old Nags-/- and eight aged-matched wild-type controls were used for 
this study. Mice were housed with minimal bedding to minimize mounding, which can 
obscure the mouse during recording. Mice were acclimated to their cages and the 
environment for 48 hours prior to the study and were recorded for 23 hours beginning at 
10:00 AM. Mice remained on NCG/Cit supplemented water for the first 23 hours. After 
the first 23 hours, the NCG/Cit supplemented water was replaced with regular water 
before the next 23 hours of recording. Recording of behavior lasted for 23 hours in order 
to give the researcher time to change the water and recalibrate the cages so that day 2 
recording could also start at 10:00 AM. Random bouts of movies were inspected after the 
experiment to determine the accuracy of the behaviors called by the recognition software. 
Incorrect behaviors were manually changed by the researcher. Results are presented as the 
average percent of time where a given behavior was observed.  
The information provided by the software provides the researchers with 
approximately 20 different behaviors. We chose to group some of these behaviors into 
seven categories for data analysis. The software recognizes and distinguishes the 
behaviors rear up, come down from partially reared, come down to partially reared, rear 
up from partially reared, rear up to partially reared, remain reared up, and remain partially 
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reared, which we grouped as “Rear up”. “Hanging” regroups the behaviors hang cuddled, 
hang vertical from hang cuddled, remain hang vertical, and remain hang cuddled as 
defined by the software. “Eat” regroups the software distinguished behaviors eat and 
chew. “Walk” regroups the software distinguished behaviors walk left, walk right, and 
walk slowly. “Sleep/no activity” regroups the software distinguished behaviors sleep and 




Mouse	  behaviors	  defined	  by	  Home	  
Cage	  Scan	  program:	  
Grouped	  by	  researcher	  for	  analysis	  
as:	  
Rear	  Up	   Rear	  Up	  
Come	  down	  from	  partially	  reared	  
Come	  down	  to	  partially	  reared	  
Rear	  up	  to	  partially	  reared	  
Remain	  reared	  up	  
Remain	  partially	  reared	  	  
Hang	  cuddled	   Hanging	  
Hang	  vertical	  from	  hang	  cuddled	  
Remain	  hang	  vertical	  
Remain	  hang	  cuddled	  
Eat	   Eating	  
Chew	  
Drink	   Drinking	  
Walk	  left	   Walking	  
Walk	  right	  
Walk	  slowly	  
Groom	   Grooming	  
Sleep	   Sleeping/no	  activity	  
Remain	  low	  
 
Table 2. Home Cage System generated behaviors were grouped into seven categories 
for behavioral analysis. 
The Home Cage System software can distinguish over 20 different mouse behaviors. 
Nineteen of these specific behaviors were grouped into seven general categories: rear up, 
hanging, eating, drinking, walking, grooming, and sleep/no activity for behavioral analysis 




Results and Discussion 
 
Voluntary Wheel 
 We first measured running activity in mice placed in cages with voluntary wheels. 
The voluntary wheel is a popular assessment of activity measurement in mice, as rodents 
are known to run a considerable distance, up to 5-6 km per day when placed in cages with 
a running wheel[126]. In this experiment, mice were introduced to the running wheel for 
24 hours prior to the beginning of data collection. On day 1, both wild type and Nags-/- 
mice were monitored for 24 hours while on NCG/Cit supplement. There is no significant 
difference in the running wheel activity of these two genotypes. In both cases, they 
exhibited high activity at the beginning of the experiment, decreased their running activity 
approximately 7-8 hours into the study, and then increased their running activity again 17-
18 hours into the study (Figure 17). This experimental set up does not provide other 
behavioral data, such as when they were hanging from the cage, eating, or grooming. 
Therefore, there is no way to determine what behaviors the mice were performing when 
not running. For example, mice are known to do the majority of their eating in the early 
evening hours.  
 Following NCG/Cit withdrawal, the WT mice did not exhibit any changes in 
running patterns compared to day 1. Nags-/-mice however, decrease their running activity 
around 6 hours post-withdrawal and did not appear to perform any running past 12 hours 
after the withdrawal (Figure 17). During high-intensity exercise, ammonia production is 
increased in skeletal muscle[127]. Once NCG/Cit was withdrawn from the water, the mice 
continued to run, which would have likely resulted in a buildup of ammonia and no 
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mechanism to remove it. Although this method does not account for other behaviors, we 
can hypothesize that high-intensity activity decreases and stops within 12 hours of 






Figure 17. Running activity of wild type and Nags-/- mice.  
Wild type and Nags-/- mice were placed in cages with running wheels, and running 
activity (in meters traveled/hour) were recorded for 24 hours on NCG/Cit supplement, and 
then for additional 24 hours after the supplement was removed. Data for each time point is 
presented as mean ±	 SEM. Statistical significance was performed using a one-way 
ANOVA. p<0.05,*; p<0.01,**; p<0.001,***; p<0.0001,****.  









































Home Cage Behavioral System 
 In order to comprehensively assess behavioral changes that occur during the 
development of hyperammonemia in mice, we used the Home Cage Scan behavioral 
monitoring system, which recorded mouse activity for 48 hours. We considered eight 
behaviors of interest: eating, drinking, hanging, walking, grooming, remaining low, 
sleeping, and rearing up.  
 During the first 24-hour period (on NCG/Cit), there is no significant difference in 
rearing up, hanging, eating, walking, and sleeping behavior (Figures 18 and 19). Wild 
type and Nags-/- mice were most active during the first half of the dark phase as 
demonstrated by decreased rest (Figure 19F) and increased hanging (Figure 19A) 
behaviors. In the second half of the dark phase, resting increased, and hanging vertical 
behaviors decreased. This is considered “normal” behavior for mice. Wild type mice 
increase their grooming, a comforting, low-stress activity, as they transition to their active 
period in the evening [123]. Nags-/-mice seem to drink more while on NCG/Cit 
supplementation (Figure 19D), which may indicate that the mice are self-medicating as a 
learned behavior that makes them feel better. Additionally, Nags-/- mice groom less in the 
dark period compared to their WT littermates (Figure 19G). 
 After the withdrawal of NCG/Cit, wild type mice appeared to exhibit the same 
activity levels compared to the first 24-hour period (Figure 18). This seems to indicate that 
NCG/Cit has no effect on the activity in healthy mice. However, Nags-/-mice decreased all 
activities nine hours following NCG/Cit withdrawal (Figures 18 and 19). Drinking and 
hanging were the first two activities to cease, approximately 12-13 hours following 


































































Figure 18. Behavior of Wild Type (A) and Nags-/- (B) mice during NCG/cit 
supplementation and following withdrawal.  
Each bar represents one hour of the study. Behaviors are broken down into percentage of 
time each behavior was performed per hour, adding up to 100%. “Unknown” represents 








Figure 19. Activity plots of wild type and Nags-/- mice with NCG/cit supplementation 
and after withdrawal.  
Hanging (A), rearing (B), eating (C), drinking (D), walking (E), sleep/no activity (F), and 
grooming (G) behaviors were analyzed for 24 hours while both wild type and Nags-/- mice 
received NCG/Cit supplement, and then for another 24 hours after NCG/Cit withdrawal. 
Boxed areas represent nighttime and thus the “active period” for rodents. Data is 
presented as an average of the percentage of time the mice were performing each activity 





Table 3. Cease of activity following the removal of NCG/Cit supplementation.
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Other activities such as walking, rearing, and grooming may continue with some 
frequency through 18-19 hours following withdrawal. Table 2 summarizes when Nags-/- 
mice stop performing each activity following the withdrawal of NCG/Cit. Attempts to 
rescue the mice with injections of NCG/Cit at 23 hours were unsuccessful, indicating that 
in mice severe hyperammonemia beyond a certain stage cannot be cured with the rescue 
drug (Data not shown). 
 The timing of NCG/cit withdrawal is something that must be taken into account 
for future studies. To maintain consistency, NCG/cit supplement was removed at 10:00 
AM for both the voluntary wheel and home cage studies. However, mice are not active 
during the day time, and possibly do not drink a significant amount of water during the 
day compared to nighttime. Therefore, experiments will be repeated with the NCG/cit 
withdrawal just prior to their active period to assess if the timing of the withdrawal affects 
the chronology of hyperammonemia.  
Even though the Nags-/- mouse recapitulates the biochemical symptoms of 
hyperammonemia in humans, there are some limitations to this model. Poor feeding and 
vomiting is seen in patients experiencing hyperammonemia [32]. Rodents do not vomit 
due to the lack of neural connections and muscle strength required to open the barrier 
between the stomach and esophagus.  Therefore, objectively measuring activity using a 
home cage behavioral system provides us with the best available method to assess early 
signs of hyperammonemia in the mice. In the Nags-/- mouse, it is the increase of lethargy 
that is indicative of developing hyperammonemia.  The decrease of activity following 
removal of NCG/Cit is not surprising given that the symptoms of hepatic encephalopathy 
in patients includes lethargy, altered level of consciousness, and coma.  
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  At the cellular level, hyperammonemia is known to have at least two effects on the 
brain; first, astrocytic swelling due to increased glutamine synthesis via glutamine 
synthase [15,128], and secondly, neuronal damage due to over-activation of the NMDA 
receptor [129,130]. Both contribute to cerebral edema. It is unknown how these cellular 
mechanisms contribute to the behavioral symptoms seen in hyperammonemic patients and 
rodents. Understanding the behavioral chronology of hyperammonemia in rodents will 
help determine the changes occurring on the cellular level. Additionally, identifying the 
cellular changes during hyperammonemia may aid in the discovery of drugs that could 
block or reverse the effect of hyperammonemia on the brain. NAGS deficiency is the only 
cause of hyperammonemia that can be prevented, using NCG. In the case of other 
hyperammonemia causing diseases, the only treatments are a strict no-protein diet, 
ammonia scavenging drugs, or hemodialysis during a hyperammonemic crisis. There are 
no drug-based therapies for neuroprotection from hyperammonemia to date. Drugs such as 
methionine sulfoximine [131], memantine, and MK-801 [20] have some success in 
protecting the brain in rodents, but their effectiveness and toxicity has not been tested in 
humans. The identification of behavioral biomarkers in the Nags-/- mouse should prove 




Chapter 4: Determination of a liquid chromatography-mass 
spectrometry method for the determination of N-carbamyl-L-




NAGS patients lack the enzyme N-acetylglutamate synthase (NAGS), which 
produces N-acetylglutamate (NAG) from L-glutamate and acetyl-CoA [6]. NAG, in turn, 
is an essential activator of the urea cycle enzyme, carbamyl phosphate synthetase I 
(CPS1), the first step in the urea cycle [51]. Thus, the absence of NAG results in a 
reduction or abolishment of CPS1 activity, leading to a block in ureagenesis and 
accumulation of ammonia in the blood [30,92]. NAGS is also present in the small 
intestine, and deficiency in the enzyme will also result in citrulline and arginine deficiency 
[21,132]. 
N-carbamyl-L-glutamate (NCG) is a functional analog of NAG that has been 
shown to be resistant to in vivo degradation, which allows the molecule to reach the liver, 
enter the mitochondria, activate CPS1 [9,52] restore ureagenesis [54] and reduce plasma 
ammonia and glutamine levels [57] in patients. NCG (Carbaglu, Orphan Europe) has been 
approved by the FDA in 2010 for the treatment of NAGS deficiency. There is some 
evidence that NCG could be beneficial in other disorders where ammonia flux is reduced, 
such as CPS1 deficiency, organic acidemias, fatty acid oxidation disorders, and hepatic 
encephalopathy [57].  
Currently, there are no established methods to measure NCG in biological samples 
or tissues. Such methods would allow one to measure how much NCG enters tissues given 
a certain dosage. Measuring NCG in samples such as plasma, urine, and feces would 
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allow one to determine absorption efficacy of the drug and compliance in taking the drug. 
Our goal was to develop a method using LC-MS to quantify NCG in the plasma, urine, 
and feces as well as liver and small intestine, Since NCG is not endogenously synthesized, 
any NCG detected with this method comes directly from treatment.  
Biological samples were obtained from a newly characterized mouse model (Nags-
/-) for NAGS deficiency [117]. As previously described, this mouse model represents the 
first reversible animal model of hyperammonemia. Nags-/- mice develop 
hyperammonemia within 12 hours following the removal of NCG and Cit. As such, these 
mice receive daily supplementation of NCG and Cit starting from birth, thus, NCG should 
be measureable in their liver, intestine, urine, feces, and plasma. The method described 
herein was adapted from previously described experiments from this lab to measure NAG 
via GC-MS and LC-MS [133,134].  
Materials and Methods 
Chemicals 
N-carbamyl-L-glutamate, trifluoroacetic acid (TFA), trichloroacetic acid (TCA), and 
acetonitrile were purchased from Sigma-Aldrich.  
Synthesis of Isotopic N-carmabyl-L-glutamate 
To be used as the internal standard, isotopic NCG (13C-NCG) was synthesized at 
American University by Dr. Monika Konaklieva and Mr. Tim Beck. 500 mg [13C5]-
glutamate (Sigma Life Science BioUltra) and 350 mg urea (Fisher) were combined with 
potassium hydroxide and water and incubated in a Discover LabMate IntelliVent Pressure 
Control System microwave for 30 min at 105°C and 300W. The mixture was then cooled 
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for 10 min at room temperature prior to placing in an ice bath and neutralized to pH 7 with 
6M HCl. The mixture was then transferred to a beaker and exposed to continuous airflow 
under a fume hood for 3 days. The presence of isotopic carbamoylated glutamate was 
identified via 1H NMR (400 MHz, D2O) via Bruker 400 spectrometer and MS (Applied 
Biosystems 3200QTrap LC/MS/MS).  
Instrumentation 
LC-MS analysis was conducted using an Agilent 1200 series LC system consisting 
of a G1311A quaternary pump, a G1322A degasser, and an ALSG1329A refrigerated 
autosampler interfaced to an APO 150EX mass spectrometer. The turboionspray source 
(TIS) was operated in positive ion mode.  Instrument control and data analysis were 
performed using ChemStation software (Agilent Technology). 
Chromatographic and Mass Spectrometer Conditions 
The mobile phase consisted of 92% Buffer A (0.1% TFA, 99.9% H2O), and 8% 
Buffer B (90% acetonitrile, 0.1% TFA, 10% H2O). Elution of analytes was carried out 
under the following setting: flow rate 0.6 mL/min, drying gas flow rate 13 L/min, 
nebulizer pressure 0.5 psig, drying temperature of 350oC, capillary voltage of 3500 
positive and negative. Mass spectrometric data were collected between 0 and 4 min, under 
selective ion monitoring for ions 191.1 (native NCG) and 195.7 (isotopic NCG). 
 
Tissue Collection 
All procedures for mice care were in accordance with the guidelines set forth by 
the American Association for Accreditation of Laboratory Animal Care and all the studies 
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were approved and supervised by the Children’s National Medical Center Institutional 
Animal Care and Use Committee (protocol number 247-09-11). Mice were housed and 
bred in the Research Animal Facility (barrier facility) under controlled temperature (68°F) 
and a 12-hour light/dark period. Mice were fed Harlan Tecklad irradiated chow (2018) 
and sterilized water. The creation of the Nags-/- has been previously described [117]. After 
weaning (typically 21 days), Nags-/- mice were maintained on water supplemented with 
NCG and Cit (each 1.0 g/L). 
Plasma was collected by cardiac puncture, as previously described [117]. Livers 
were frozen in liquid nitrogen, and then homozgenized. Intestines were collected and 
intestinal epithelial cells were isolated as previously described [117]. Urine was collected 
onto filter paper from mouse at the time of sacrifice. The urine was then extracted in water 
and shaken vigorously. Feces was collected from the mouse at the time of sacrifice and 
homogenized. 13C-NCG was added to all the samples prior to analysis. 
Statistical Analysis 
All statistical analyses were performed using Prism software, version 5 (GraphPad, 
San Diego, CA). The minimal level of confidence at which experimental results were 
considered significant was p<0.05. Statistical significance was determined with a t-test 
comparing NCG-treated mice to non-supplemented, wild type mice. In all cases, data is 





Results and Discussion 
 
 In order to measure NCG in clinically relevant samples, we developed a stable 
isotope dilution method using LC-MS, derived from a similar method for measurement of 
NAG [134]. Isotopic NCG was prepared from glutamate and urea, which has a mass-to-
charge ratio (m/z) of 196 due to the universal 13-C label of carbons in the glutamate 
(Figure 20). NCG and 13C-NCG are detected and quantified by selected ion monitoring 
mass spectrometry. 13C-NCG and NCG have the same retention time (Figure 21). Thus, 
13C-NCG acts as an ideal standard in order to identify native NCG in the sample. This 
method allows the detection of as little as 0.001 mM NCG in a sample.  
 NCG is not endogenously synthesized in mammals. Though Grisolia and Cohen 
believed that NCG was the natural intermediate in the synthesis of citrulline [49,50], in 
1958 NAG was isolated from liver preparations, suggesting that NAG is indeed the 
natural cofactor in carbamyl phosphate synthesis [51]. As a result, we expected that wild 
type mice, never given NCG supplementation, would have no detectable amount of NCG 
in any of their tissues. Additionally, wild type mice given NCG supplementation over a 
period of a few days, as well as Nags-/- mice, should have detectable amounts of NCG in 
all relevant tissues and body fluids.  
  We were surprised to find a detectable amount of NCG in liver tissue of wild type, 
non-supplemented mice (Figure 22). We hypothesized that the presence of NCG in 
untreated liver was due to a reaction artifact caused by the addition of the TCA to the 
homogenized liver. To test this hypothesis, we combined glutamate and urea, urea and 
carbamyl phosphate, and glutamate and carbamyl phosphate with 30% TCA. Analysis of 






Figure 20. Structure of N-carbamylglutamate and isotopic N-carbamylglutamate.  











Figure 21. Representative chromatogram of N-carbamylglutamate.  
Isotopic NCG with a molecular weight of 196 is represented by dashed lines, while the 
native NCG with a molecular weight of 191 is represented by a solid line. In this 





Figure 22. Concentration of NCG in liver samples.  
Livers were collected from untreated wild type mice, wild type mice treated with NCG for 
3 days, and 6-week-old Nags-/- mice. Livers were homogenized and analyzed for NCG 
content. NCG concentration (in µmol) was normalized to µg protein used. Liver NCG 
concentrations in treated mice are not statistically significant from WT control. (WT 




phosphate and glutamate in the presence of TCA produces a peak that corresponds to 
NCG (Figure 23). From the structures of glutamate (Top, Figure 23) and carbamyl 
phosphate (Bottom, Figure 23), one can deduce that NCG can be synthesized by 
spontaneous reaction. We believe that the appearance of NCG in wild type control 
samples is an artifact due to the addition of TCA. Thus, we need to explore other methods 
of precipitating protein from samples that do not involve the addition of acid. Such 
methods may include filtering the sample through columns to remove the protein.  
The Nags-/- mice have a larger concentration of NCG in their intestines compared 
the wild type mice treated with NCG (Figure 24). This may be due to competition 
between NAG and NCG for CPS1 in the wild type mice. Since NAG has a stronger 
affinity for CPS1 than NCG, the latter may not bind as efficiently to CPS1 when NAG is 
present, and thus may not stay in the cell. NCG was not detected in the intestinal 
epithelium of non-supplemented mice (Figure 24). If sufficient amounts of NCG are 
transported into intestinal epithelial cells, it should activate CPS1 in the absence of NAG, 
which would result in citrulline production. However, previous experiments have shown 
that supplementation with NCG but not Cit results in 50% fatality after two weeks, 
suggesting that the Nags-/- mice supplemented with NCG are citrulline/arginine deficient. 
One hypothesis is that the Nags-/- mice may undergo stresses that lead to arginine 
deficiency that cannot be compensated by the amount of citrulline produced via the NCG 
activation of CPS1 in the intestine.  Arginine is a precursor for cellular pathways involved 
in wound healing [109,135-137] and immunity [138-140]. For example, arginine is a 
precursor for nitric oxide, an anti-inflammatory agent and a promoter of vascular health 



























Figure 23. Combination of glutamate and carbamyl phosphate in the presence of 
TCA produces a product that corresponds to NCG.  
Solutions of glutamate and carbamyl phosphate were combined and treated with 30% 
TCA before LCMS analysis. Top structure= glutamate; lower structure=carbamyl 
phosphate. Both NCG and isotopic NCG are eluting at 2.8 minutes in this chromatogram. 




Figure 24. Concentration of NCG in intestinal epithelial cells. 
Small intestine was collected from untreated wild type mice, wild type mice treated with 
NCG for 3 days, and 6-week-old Nags-/- mice. Intestinal epithelial cells were isolated as 
described, homogenized and analyzed for NCG content. NCG concentration (in µmol) 




production decreased 30 minutes after a stressful period and remained low 3 days 
thereafter [142]. Circumstances that involve arginine deficiency, such as a wound or 
stress, can result in a decline in immune function and vascular health. If the concentration 
of NCG in intestinal cells is not promoting a sufficient amount of citrulline production to 
overcome this deficiency, it could potentially lead to a fast decline in health.   
As expected, NCG is detected in the plasma and urine of supplemented mice, and 
is undetectable in non-supplemented control mice (Figures 25-26). The presence of NCG 
in the plasma and urine of supplemented mice is clinically relevant. A study in which 
radioactive NCG was given to healthy subjects showed that NCG could be measured in 
the plasma within 3 hours of administration, and by 12 hours, 40% of the dose was 
eliminated in urine and 22% eliminated in feces [143]. Currently, there are no clinical 
methods to detect NCG in patient samples. The ability to do so can help clinicians 
determine if patients are being compliant in taking medication. Additionally, there is an 
increasing use of NCG by athletes apparently to increase performance. If NCG eventually 
gets classified as a performance-enhancing drug, the presence of this drug could be 
measured easily in a blood or urine sample.  
The presence of NCG in fecal samples of non-supplemented wild type mice was 
surprising (Figure 27). One possible explanation for this unexpected observation is gut 
bacteria that produce NCG. This hypothesis would also explain the presence of NCG in 
wild type liver since metabolites produced in the gut can eventually enter the liver through 
the portal vein. If a NAGS deficient person has gut bacteria producing NCG, then it is 




Figure 25. Concentration of NCG in plasma. 
Plasma was collected from untreated wild type mice, wild type mice treated with NCG for 
3 days, and 6-week-old Nags-/- mice. NCG concentration is expressed in µM. (WT control 





Figure 26. Concentration of NCG in urine. 
Urine was collected on filter paper from untreated wild type mice, wild type mice treated 
with NCG for 3 days, and 6-week-old Nags-/- mice. Urine spots were then eluted in water 
and analyzed for NCG content. NCG concentration is expressed in µM. (WT control n=5, 





Figure 27. Concentration of NCG in feces. 
Feces were collected from untreated wild type mice, wild type mice treated with NCG for 
3 days, and 6-week-old Nags-/- mice. Samples were homogenized and analyzed for NCG 
content. NCG concentration (in µmol) was normalized to µg protein. Fecal NCG 
concentrations in treated mice are not statistically significant from WT control. (WT 




masking the disorder that could go undetected for life. This may also account for late-
onset cases, where a deficiency is discovered after the affected individual experiences a 
stress-inducing hyperammonemic crisis brought on by disease, surgery, or pregnancy 
and/or delivery. Clearly, this hypothesis will need to be explored further. One approach 
would be to treat wild type mice with antibiotics, which would destroy gut bacteria, and 
then analyze their NCG content.  
In conclusion, we have developed a method for the detection of NCG in biological 
samples. This method is clinically relevant and can be used to measure NCG 
concentrations in patient samples to confirm patient compliance or toxicity. Methods to 
measure NCG in liver and fecal samples will need to be refined, as NCG appears in non-
supplemented control mice. We believe this could be an artifact of the method of sample 
preparation. Another hypothesis that warrants further exploration is the possibility of 
NCG-producing gut bacteria. Much needs to be learned about the intestinal flora, and the 
identification of a strain that produces NCG may explain the rarity of NAGS deficiency. 
Our hope is to use this method to explore the unknowns concerning NCG pharmacology, 
such as uptake and clearance kinetics. As the transport mechanism of NCG is unknown 
understanding it can help determine if there are drugs that would compete for transport, or 
potentially how clinicians can enhance the transport of this poorly-absorbed drug.  
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Chapter 5:  Future Directions 
 
Identifying drugs that have a neuroprotective effect against hyperammonemia  
 
 The use of the NAGS deficient mouse model provides opportunities that extend far 
beyond urea cycle disorders. Hyperammonemia is a result of many disease states, 
including organic acidemias, fatty acid oxidation diseases, acute and chronic liver failure, 
certain surgeries, and chemotherapy.  Though the deficient or insufficient urea cycle 
occurs in the liver, the long-term damage of hyperammonemia occurs in the brain. 
Ammonia quickly crosses the blood brain barrier and has deleterious consequences on 
astrocytes and neurons. Patients affected with hyperammonemia develop a wide range of 
neuro-cognitive disorders, and if untreated, coma and possibly death. Currently, the 
treatment for hyperammonemia includes dietary manipulation, sterilization of the bowel, 
alternate pathway therapy for ammonia removal or liver transplantation. There are no 
specific treatments to directly protect the brain from hyperammonemia. We plan to use 
this mouse model to further understand the molecular mechanisms underlying 
hyperammonemia, as well as potentially identify drugs that may protect the brain from 
ammonia toxicity.   
We have established the behavioral chronology of hyperammonemia in the Nags-/- 
mice following NCG withdrawal, with the earliest symptoms developing within 12 hours. 




Testing known neuroprotective drugs in Nags-/- mouse 
We have chosen three drugs that have been reported to protect the brain against 
hyperammonemia in rodents. The first, methionine sulfoximine (MSO), is a glutamate 
synthase inhibitor that blocks the condensation of ammonia and glutamate into glutamine. 
Ammonia entering the brain is rapidly incorporated into glutamine via glutamine synthase 
expressed in astrocytes. Glutamine is increased in hyperammonemic individuals. MSO 
works by producing MSO-phosphate, which binds to the active site and inhibits glutamine 
synthase [144]. In cultured astrocytes and hyperammonemic rodents, inhibition of 
glutamine synthetase by pre-treatment with methionine sulfoximine prevents an increase 
in cortical glutamine, cortical water content (edema), and intracranial pressure [145]. 
Another study showed that MSO reduces glutamine synthase activity by 57% and 
glutamine accumulation by 71% compared to control groups [146]. In a model of induced 
liver failure, administration of MSO drastically increased animal survival and reduced 
glutamine synthase activity [144].  
 Increased activity of the NMDA receptor has also been implicated in 
hyperammonemia-induced neurological damage. Elevated ammonia concentrations lead 
to a down-regulation in astrocyte glutamate transporters glial glutamate transporter 1 
(GLT1) and glutamate aspartate transporter (GLAST), resulting in a buildup of 
extracellular glutamate [147-149]. This extraceullar glutamate causes overstimulation of 
the NMDA receptor and excessive influx of ions, resulting in cell swelling and 
neurodegeneration [18,19]. Hyperammonemia induced by acute liver failure leads to 
activation of the NMDA receptors and subsequently oxidative stress and neuronal 
damage, leading to death. Both MK801 and memantine function to block the NMDA 
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receptor, doubling survival time of rodents subjected to chemical-induced liver injury 
[20]. 
We plan to test all three drugs using Nags-/- mice. Drugs will be administered 
prior to NCG/Cit withdrawal. Survival time as well as behavior will be assessed and 
compared to a control group of untreated, non-NCG supplemented Nags-/- mice. Alzet 
osmotic pumps will need to be inserted subcutaneously for the MK801 and memantine 
studies. This is necessary because MK801 and memantine are cleared quickly. These 
pumps provide a convenient and reliable method for the controlled delivery of drugs. 
MSO remains in the body for three days after administration, and will be injected 
intraperitoneally 3 hours prior to NCG withdrawal. We expect these drugs to act as 
neuroprotective agents and thus prolong the life of the mouse, which will be measured 
using the Home Cage Behavioral System. Additionally, we will also collect brain, liver, 
and plasma of these mice to assess transcriptional and proteomic changes that occur in 
these tissues during the time course of hyperammonemia. Analysis of these data will 
hopefully uncover molecular and cellular mechanisms underlying hyperammonemia in the 
brain. Again, we believe our mouse model is of hyperammonemia is unique because other 
confounding factors (such as exogenous toxins or surgery) are not involved.  
Identification of the N-carbamylglutamate transporter 
 
NCG is an FDA approved drug for the treatment of NAGS deficiency, with the 
potential for treatment of hyperammonemia from other causes. Despite this, little is 
known about its pharmacology, for example transport across plasma membrane and 
mitochondria of liver and small intestine, how efficiently it binds to CPS1, and how it is 
eliminated. Understanding the transport mechanisms of NCG is important for two reasons. 
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First, in the cases of NAGS deficiency and possibly other inborn errors of 
metabolism[58], activation of CPS1 by NCG is crucial for maintaining ureagenesis. 
Decreasing or blocking transport could potentially lead to hyperammonemia. Therefore, it 
is important to know which transporters are involved and whether there could be 
competition for these transporters by various drugs. Secondly, use of NCG is promoted as 
a muscle-building dietary supplement, which could potentially lead to wide spread use or 
abuse of this drug. Identifying any adverse drug interactions due to competition for 
transporters is therefore significant. Ultimately, we will use our previously described LC-
MS assay, which was adapted from an LC-MS assay for detection of NAG [133,134], to 
determine if cells and tissues have successfully taken up NCG.   
 In order to determine which transporters are involved, we will use affinity labeling 
with activated NCG, proteomic analysis of liver and intestinal mitochondria and siRNA 
knockdown of candidate transporters in liver cells. NCG is anionic at neutral pH, therefore 
we hypothesize that likely candidates will include anionic amino acid transporters. We 
have shown that HepG2 cells import NCG (Figure 28), and therefore the HepG2 line will 





Figure 28. HepG2 and A549 cell lines take up NCG.  
HepG2 and A549 (a lung cell line) were exposed to NCG for 3 hours. Cells were lysed, 
and analyzed for NCG content. Since A549 cells take up NCG, the transporter is likely to 






Identification of the plasma membrane and mitochondrial transporters for NCG by 
affinity labeling  
 
 The first approach uses affinity labeling followed by proteomic mass spectrometric 
analysis of membrane proteins. 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC) 
is a crosslinker that reacts with the epsilon amino group of lysine residues in proteins. 
EDC-activated NAG was used to identify the NAG binding site of CPS1 [150]. We 
believe that we could activate NCG with EDC, and then add it to cells, resulting in EDC-
NCG binding to and cross-linking with its plasma membrane transporter. Then, plasma 
membrane proteins will be isolated via SDS-PAGE gel, subjected to trypsin digestion, and 
then fragments will be analyzed by mass spectrometry in the proteomics core facility. 
Modifications of lysine residues from cross-linking with EDC-NCG will result in a loss of 
a tryptic digestion site and a shift in the mass of the peptide with the attached NCG. These 
experiments will be repeated with mouse intestinal epithelial cells to determine if the 
NCG transporter is the same in the intestine. Additionally, we will use a similar approach 
using isolated liver and intestinal mitochondria to identify the mitochondrial transporters.  
 
Using siRNA knockdown to identify the NCG transporters  
 
We also plan to use siRNA knockdown experiments to demonstrate that putative 
transporters identified in the proteomics experiments are successful in transporting NCG. 
For this experiment, we will use hepatocytes isolated from Nags-/- mice, which will allow 




If we are unable to identify the transporter using the proteomics methods outlined 
above, we will use a siRNA knockdown screen. Primary hepatocytes from Nags-/- mice 
will be isolated and cultured under conditions that maintain hepatocyte metabolism, 
apical/basal polarization and expression of transporters [151,152]. We will use methods 
that have been shown to silence organic anion transporters in hepatocytes [153,154]. After 
transporters have been silenced, hepatocytes will be cultured in media containing NCG. 
Cells in which NCG transport has not been compromised will produce urea, which can be 
visualized using a colorimetric assay. If the NCG transporter has been silenced, 
ureagenesis will not occur. Transport or lack of transport can be confirmed using our LC-






Chapter 6: Conclusions 
 
 
Hyperammonemia is a state of metabolic disturbance characterized by an 
increased concentration of ammonia in the plasma. Hyperammonemia can occur in 
patients with untreated or undiagnosed urea cycle disorders, as well as in patients with 
defects in fatty acid oxidation, cirrhosis, acute liver failure, Reye syndrome, and as a 
complication from certain surgeries and chemotherapy. Though hyperammonemia occurs 
when the urea cycle, a liver pathway, is compromised, hyperammonemia negatively 
affects the brain. Elevated plasma ammonia compromises astrocyte and neuronal function, 
causing cerebral edema and neuronal damage, which results in patient symptoms 
including lethargy, vomiting, seizures, coma, and death. Currently, treatment for 
hyperammonemia is focused on the liver, by decreasing protein load, using ammonia 
scavenging drugs (which are not 100% effective), dialysis, or liver transplant. A thorough 
understanding of how ammonia affects pathways in the central nervous system and 
treatments that protect the brain from ammonia are desperately needed. 
One step in understanding the pathophysiology of hyperammonemia is the 
development of a clean, inducible rodent model of hyperammonemia. Current models of 
hyperammonemia involve procedures with confounding factors or urea cycle deficient 
mouse models that do not survive into adulthood. Here we describe the first clean, 
inducible, rescuable animal model of hyperammonemia: a mouse model of N-
acetylglutamate synthase (NAGS) deficiency that can be rescued with a combination of 
N-carbamylglutamate (NCG) and citrulline. This model recapitulates the human disease, 
as Nags-/- mice become lethargic, ataxic, comatose, and hyperammonemic and develop 
abnormal amino acid profiles within 24 hours of NCG/cit withdrawal. Using this mouse 
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model and methods to quantitate behavior, we showed that following NCG/cit withdrawal, 
Nags-/- mice decrease all behaviors and become severely lethargic within 22 hours.  
The development and usefulness of this mouse model extends far beyond NAGS 
deficiency. Since this mouse develops hyperammonemia solely due to one factor, the 
blockage of ureagenesis, we can use this mouse to study hyperammonemia and be 
confident there are no other confounding factors contributing to the development of the 
disease state. Using the behavioral chronology, we plan to use this model to identify novel 
compounds that may offer neuro-protection from hyperammonemia. These drugs would 
transform the treatments of both urea cycle disorders and acute or chronic liver failure.  
Additionally, the Nags-/- mice will be used as a model to understand the 
pharmacology of the drug NCG. NCG is sold under the name Carbaglu and approved by 
the FDA for the treatment of NAGS deficiency. However, this drug is now being 
prescribed off label for the treatment of CPS1 and organic academia disorders, and used as 
a performance-enhancing supplement in athletes. The increasing use of this drug means 
that physicians now need to be aware of any other drugs that may interact with or inhibit 
NCG. The development of an LCMS method to analyze concentrations of NCG in liver, 
intestine, plasma, urine, or feces will aid in the enhanced understanding of NCG 
pharmacology. This method can be used by clinicians to analyze the efficacy of NCG in 
patients, simply by collecting plasma or urine. We plan to use the Nags-/- mice and the 
LCMS method to identify the NCG transporter, which will enhance our understanding of 
NCG pharmacology.  
In conclusion, we have developed a novel, improved animal model of 
hyperammonemia, which we plan to use to increase the understanding of the 
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pathophysiology of this disease. By understanding how ammonia affects the brain, we 
hope to develop novel drug treatments to improve the health and quality of life of patients 




Appendix:  Urea Cycle Enzyme expression in HepG2 and IEC-
6 cell lines 
 
 
Methods and Materials 
 
Total RNA was extracted from cells using the TRIzol reagent (Invitrogen). cDNA was 
generated using the Superscript III First strand synthesis kit (Invitrogen).  Primers for 
human HepG2 cells and rat IEC-6 cells are listed in Table 3. Real-time PCR analysis was 
carried out using the 7900 HT Fast Real Time PCR System (Applied Biosciences) and 
SDS version 2.3 software using iQ SYBR green supermix (Bio-Rad). PCR reactions were 
carried out as follows: one cycle of 95°C for 2 minutes, followed by 40 cycles of 95°C 30 
seconds, 60°C 30 seconds, 72°C seconds, and a dissociation step of 95°C 15 seconds, 




Gene	   Species	   Orientation	   Sequence	  
NAGS	   Human	   FWD	   5’-­‐CCGCGGCCTACGGCTCCCTCGGGCTGTCT-­‐3’	  
REV	   5’-­‐GCGGGCAGGTTCACGTTACTCAGGACCTT-­‐3’	  
Rat	  
	  
FWD	   5’-­‐CCTACCCCCACGGCACCTTCTGGCTG	  -­‐3’	  
REV	   5’-­‐GCGGGCAGGTTCACGTTGCTCAGGA	  -­‐3’	  
CPS1	  
	  
Human	   FWD	   5’-­‐TCCTGATACTACTGCTCTGGATGAACT-­‐3’	  
REV	   5’-­‐CCCGGTCCTCCCGCGATCAAAATCCCATCAT-­‐3’	  
Rat	   FWD	   5’-­‐ATCTGAGGAAGGAGCTGTCT-­‐3’	  
REV	   5’-­‐AAAACCACTTCTCAATGGAT-­‐3’	  
OTC	  
	  
Human	   FWD	   5’-­‐GCGAAATTCGGAATGCACCTTCAGGCAGCTACT-­‐3’	  
REV	   5’-­‐TCTGCCTCTGGGAACACTAGTGATCGAGGAGAA-­‐3’	  
Rat	   FWD	   5’-­‐ATGACAGATGCAGTGTTAGC-­‐3’	  
REV	   5’-­‐CAGGATCTGGATAGGATGAT-­‐3’	  
ASS	   Human	  
Rat	  
FWD	   5’-­‐TCGTGCATCCTCGTCGTGTGGCTGAA-­‐3’	  
REV	   5’-­‐CCACAAACTCCCTGCTGACATCC-­‐3’	  
ASL	  
	  
Human	   FWD	   5’-­‐GAGGTGCGGAAGGCCATCAATGT-­‐3’	  
REV	   5’-­‐TTGGTGCAGTAGAGGATGAGGTCC-­‐3’	  
Rat	   FWD	   5’-­‐GGAATTCAACTTTGTGCAGCTCTCCG-­‐3’	  
REV	   5’-­‐AACACAGCCTCCTTGTCTTCCTGT-­‐3’	  
ARG1	  
	  
Human	   FWD	   5’-­‐GCAGAAGTCAAGAAGAACGG-­‐3’	  
REV	   5’-­‐GGTTGTCAGTGGAGTGTTG-­‐3’	  
Rat	   FWD	   5’-­‐TCACACTGACATCAACACTCCGCT-­‐3’	  
REV	   5’-­‐TTCCCAGCTTGTCCACTTCAGTCA-­‐3’	  
GAPDH	  
	  
Human	   FWD	   5’-­‐CGCGGGGCTCTCGAGAACATCATC-­‐3’	  
REV	   5’-­‐CAGGTCCACCACTGACACGTTGGCA-­‐3’	  
Rat	   REV	   5’-­‐GGCTGCCCAGAACATCATCCCTGCAT-­‐3’	  





FWD	   5’-­‐GGCTGGCCGGGACCTGACTGACTA-­‐3’	  
REV	   5’-­‐AGCCGTGGCCATCTCTTGCTCGAAG-­‐3’	  
Rat	   FWD	   5’-­‐GGCTGGCCGGGACCTGACAGACTAC-­‐3’	  
REV	   5’-­‐GCAGTGGCCATCTCCTGCTCGAAGTC-­‐3’	  
 






Figure 29. Expression of urea cycle enzymes in HepG2 liver carcinoma cells (A) and 
IEC-6 intestinal epithelial cells (B). 
 Expression was quantitated via RT-PCR. Ct (cycle threshold) values for transcripts are 
expressed as (34-Ct) using 34 as a theoretical “no expression” value for RT-PCR. 
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